AI Article Synopsis
- The 5-year relative survival rate for pancreatic cancer is the lowest among all cancers at only 13%, with KRAS gene mutations found in about 90% of patients.
- Advances in genomic testing allow for the identification of genetic alterations in patients without the KRAS mutation, known as KRAS wild-type, which can guide targeted therapy.
- These alterations include a range of genetic changes and may present opportunities for tailored treatment approaches through clinical trials or existing drugs, with notable efficacy shown in some studies.
Article Abstract
The 5-year relative survival rate for pancreatic cancer is currently the lowest among all cancer types with a dismal 13%. A Kirsten rat sarcoma virus (KRAS) gene mutation is present in approximately 90% of patients with pancreatic cancer; however, KRAS-specific drugs are not yet widely used in clinical practice for pancreatic cancer, specifically the KRAS variant. Advances in genomic testing revealed an opportunity to detect genetic alterations in a subset of patients with no KRAS mutation termed KRAS wild-type. Patients with KRAS wild-type tumors have a propensity to express driver alterations, hence paving the way for utilizing a targeted therapy approach either via clinical trials or standard-of-care drugs. These alterations include fusions, amplifications, translocations, rearrangements and microsatellite instability-high tumors and can be as high as 11% in some studies. Here, we discuss some of the most notable alterations in KRAS wild-type and highlight promising clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11523-024-01088-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!